Equities

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)17.24
  • Today's Change0.58 / 3.48%
  • Shares traded948.00k
  • 1 Year change-23.04%
  • Beta0.6243
Data delayed at least 15 minutes, as of Sep 19 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell1

Share price forecast in CNY

The 4 analysts offering 12 month price targets for Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd have a median target of 21.57, with a high estimate of 26.03 and a low estimate of 17.01. The median estimate represents a 25.11% increase from the last price of 17.24.
High51.0%26.03
Med25.1%21.57
Low-1.3%17.01

Dividends in CNY

Historical dividend information is not available for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in CNY

On Aug 30, 2024, Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd reported 2nd quarter 2024 earnings of 0.364 per share.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+126.14%
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd reported annual 2023 earnings of 2.50 per share on Mar 15, 2024.
Average growth rate+6.98%
More ▼

Revenue history & estimates in CNY

of 20.05bn.
Average growth rate+6.69%
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd had revenues for the full year 2023 of 75.52bn. This was 6.68% above the prior year's results.
Average growth rate+4.03%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.